Biomx Inc
PHGE3.930USD
-0.580-12.72%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
5.54MCap. mercado
PérdidaP/E TTM
Más Datos de Biomx Inc Compañía
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Información de Biomx Inc
Símbolo de cotizaciónPHGE
Nombre de la empresaBiomx Inc
Fecha de salida a bolsaDec 18, 2018
Director ejecutivoSolomon (Jonathan Eitan)
Número de empleados52
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 18
Dirección22 Einstein St.
CiudadNESS-ZIONA
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísIsrael
Código postal7414003
Teléfono972723942377
Sitio Webhttps://www.biomx.com/
Símbolo de cotizaciónPHGE
Fecha de salida a bolsaDec 18, 2018
Director ejecutivoSolomon (Jonathan Eitan)
Ejecutivos de Biomx Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-1.00%
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Mr. Gregory Merril
Mr. Gregory Merril
Independent Director
Independent Director
--
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-1.00%
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 1 de feb
Actualizado: dom., 1 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
Otro
65.03%
Accionistas
Accionistas
Proporción
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
Otro
65.03%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
26.70%
Corporation
12.29%
Holding Company
3.69%
Venture Capital
3.36%
Private Equity
2.50%
Research Firm
1.49%
Individual Investor
1.33%
Investment Advisor/Hedge Fund
0.36%
Investment Advisor
0.23%
Otro
48.05%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
41
528.98K
34.65%
-249.43K
2025Q3
38
10.55M
39.72%
-5.15M
2025Q2
48
19.36M
73.97%
+6.20M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Deerfield Management Company, L.P.
131.27K
8.6%
--
--
Sep 30, 2025
Cystic Fibrosis Foundation
131.27K
8.6%
+37.18K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
131.23K
8.6%
--
--
Sep 30, 2025
Alyeska Investment Group, L.P.
83.72K
5.48%
+83.72K
--
Sep 30, 2025
Centaurus Investments Limited
56.32K
3.69%
+56.32K
--
Apr 21, 2025
AMR Action Fund LP
46.15K
3.02%
+30.07K
+187.05%
Sep 30, 2024
Telmina Ltd
29.49K
1.93%
+14.54K
+97.30%
Sep 30, 2024
Nimble Ventures LLC
26.85K
1.76%
--
--
Sep 30, 2024
J.P. Morgan Securities LLC
22.63K
1.48%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
